excessive risk of toxicity in nontargeted zones, the it.-injected drugs should be concentrated at specific locations within the spinal canal. For example, in pain management therapies, morphine needs to reach specific receptor sites located on the dorsal horns of the spinal cord to elicit an analgesic effect [10][11][12]. In the case of it. morphine administration, the drug molecules need to transport across the pia mater and then diffuse through spinal cord tissue in order to reach the dorsal horns. it.-administered therapeutics for chemotherapy also have small local targets in which similar transport processes are necessary in order to cross the ependymal sur-faces in the spinal canal and then diffuse to the ing large amounts of drug spread throughout the entire brain and spinal canal, which may cause side effects.
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We have recently shown that pulsatile CSF motion causes intense mixing of it.-delivered drugs [9] . Even though CSF flow within the spi-nal canal has a small Reynolds number, there is still vivid fluid exchange because the fluid lami-nae are intertwined due to CSF pulsations. In this paper, we present a novel approach of using magnetically guided nanoparticles, which are capable of being functionalized with different types of drugs, for localizing and concentrating the particles at specific locations in an in vitro model of the human spine. Aim: We aimed to magnetically guide and locally confine nanoparticles in desired locations within the spinal canal to achieve effective drug administration for improved treatment of chronic pain, cancers, anesthesia and spasticity.
Materials & methods:
We developed a physiologically and anatomically consistent in vitro human spine model to test the feasibility of intrathecal magnetic drug targeting. Gold-coated magnetite nanoparticles were infused into the model and targeted to specific regions using external magnetic fields. Experiments and simulations aiming to determine the effect of key parameters, such as magnet strength, duration of magnetic field exposure, magnet location and ferrous implants, on the collection efficiency of superparamagnetic nanoparticles in targeted regions were performed. Results: An 891% increase in nanoparticle collection efficiency within the target region was achieved using intrathecal magnetic drug targeting when compared with the control. Nanoparticle collection efficiency at the target region increased with time and reached a steady value within 15 min. Ferrous epidural implants generated sufficiently high-gradient magnetic fields, even when magnets were placed at a distance equal to the space between a patient's epidermis and spinal canal.
Conclusion:
Our experiments indicate that intrathecal magnetic drug targeting is a promising technique for concentrating and localizing drugs at targeted sites within the spinal canal for treating diseases affecting the CNS.
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Intrathecal (it.) drug delivery has been a stan-desired site of action. Such issues are currently dard treatment for different CNS disorders, such overcome by using high drug doses so that the as leptomeningeal metastases [1] [2] [3] and spasticity required concentration reaches the target region [4] , and has been widely used for pain manage-in order to aid diffusion into the spinal cord and ment [5] and in spinal anesthesia [6, 7] . Recent produce a therapeutic effect. Due to CSF pulsa-attempts even aimed at using it.-delivered siRNA tions, as well as the presence of nerve roots and to treat diseases of the CNS [8, 9] . Once injected, trabeculae, which enhance mixing, these high the drugs are rapidly dispersed within the spinal drug concentrations are rapidly spread through-canal by both molecular diffusion and by the out the entire CNS. At this point, there is no pulsatile motion of cerebrospinal fluid (CSF) [9] . delivery technique to confine drugs locally where To maximize the therapeutic effect without it is needed in high concentrations without hav- ) nanoparticles can be preferentially con-fined within an area of interest by guiding the particles with an external magnetic field. We have also provided computational results that aided in determining the optimal magnetic field for efficient it. magnetic drug targeting (it.-MDT). If this novel technique can be successfully uti-lized with the required drug conjugated to the nanoparticles, the drugs can be locally delivered within the spinal canal at high concentrations, minimizing unwanted side effects of the drug away from the target region.
Our approach builds on the methods of MDT. MDT is a type of active drugtargeting method in which drugfunctionalized magnetic nanoparticles (MNPs) are injected into the body and then localized to the target region by use of an external magnetic field. The drug will then desorb from the MNPs and begin its therapeutic mechanism of action. The most notable benefits of MDT reside in local drug action and minimi-zation of systemic side effects. Until now, MDT methods have been mainly used to target drugs delivered systemically through blood vessels and have shown great promise [13] [14] [15] [16] [17] [18] [19] [20] [21] . The novelty of our approach lies in applying the methods of MDT within the CSF-filled spinal canal, not in blood vessels, in order to achieve a localized thera-peutic effect using much smaller drug doses and substantially reducing systemic toxicity for novel treatments of CNS diseases.
This paper is organized as follows: nano-particle synthesis is presented first, followed by a description of our in vitro human spine model and experimental setup. The 'Results' section pres-ents the MNP characterization and the outcomes from experiments in order to determine MNP collection efficiency (CE) as a function of mag-netic field strength, duration of magnetic field exposure and distance between the target loca-tion and injection site. Preliminary results from implantassisted it.-MDT experiments are also presented. The paper closes with a discussion of our experimental results and conclusions. the nanoparticles at different regions within the human spine model. In this section, we describe: the materials and methods used for nanoparticle synthesis; our in vitro human spine model; the simulations used to determine optimal mag-netic fields; and our experimental procedure to determine MNP CE. n Synthesis of gold-coated Fe O 3 4 nanoparticles The nanoparticles utilized for all of our experi-ments had a Fe 3 O 4 core with diameter varying between 8 and 12 nm, as shown in Figure 1A . Fe 3 O 4 cores within this diameter range are ben-eficial because they display the property of super-paramagnetism, which means they exhibit net magnetization only in the presence of an external magnetic field. Superparamagnetism allows the nanoparticles to transport freely throughout the spine model until they are in the presence of the externally applied magnetic field, which then acts to trap the nanoparticles at that defined location. Once the applied magnetic field is removed, these superparamagnetic nanoparticles lose their previ-ously induced magnetization and redisperse in the fluid. The nanoparticle cores were synthesized by a coprecipitation technique, described in Mandal et al. and various other articles, using ferrous and ferric salts to form Fe 3 O 4 [22] . These superpara-magnetic Fe 3 O 4 cores were then coated with a gold layer of varying thickness between 8 and 15 nm by a surface adsorption technique. The overall hydro-dynamic diameter of the particles was found to be between 20 and 25 nm, as shown in Figure 1B . The gold coating on the Fe 3 O 4 served two purposes: it prevented oxidation of the Fe 3 O 4 core into maghemite by forming an inert biocompatible protective coating; and it also formed an excellent platform for conjugating drugs to the nanoparticle surface, since gold has a natural affinity for thiol bonds [23] . These particles were suspended in a Triton™ X-100 (Fisher Scientific, PA, USA) surfactant solution in order to introduce micelles and help prevent agglomeration. The nanoparticles were characterized by using transmission elec-tron microscopy (TEM), energy-dispersive x-ray spectroscopy (EDS) and superconducting quan-tum interference device (SQUID) magnetometry. More details regarding the MNP synthesis can be found in the Supplementary inFormation (see online at www.futuremedicine.com/doi/suppl/10.2217/ NNM.13.69).
Materials & methods
In all of our experiments, we used externally placed permanent magnets to target superpara-magnetic gold-coated Fe 3 O 4 nanoparticles at specific locations within an in vitro model of the human spine. The main aims of these experiments were to systematically study the spatial distribu-tion of the MNPs in the presence of static magnetic fields within the it. space, and to investigate the possibility of localizing and concentrating 
